Zacks, S.; Rogatko, A.; Babb, J. - In: Statistics & Probability Letters 38 (1998) 3, pp. 215-220
We present an adaptive dose escalation scheme for cancer phase I clinical trials which is based on a parametric quantal response model. The dose escalation is Bayesian-feasible, Bayesian-optimal and consistent. It is designed to approach the maximum tolerated dose as fast as possible subject to...